General

For heart attack patients unwilling to enroll in traditional rehabilitation programs, what could be a good alternative?

The American Heart Association has recently reported a study in which patients who have suffered a heart attack, and were unwilling or unable to enroll in cardiac rehabilitation programs, had success with tai chi. Those in the group of patients who were attending tai chi practices more often performed more moderate-to-vigorous physical activity over a [...]

2017-11-07T12:22:02+00:00November 24, 2017|General|

How can immunotherapies for cancer treatment be further developed and encouraged?

The NIH and a consortium of biotechnical companies have created PACT, or the Partnership for Accelerating Cancer Therapies, to encourage the development of new immune based treatments for cancer. In some types of cancer, immunotherapies have created dramatic change in the success of treatment. Who is involved in PACT? And what are its goals? http://bit.ly/2xB85zR

2017-11-07T12:21:57+00:00November 21, 2017|General|

Can expanded access give insight into the future success or failure of a new treatment?

As patients who are receiving treatments via expanded access for diseases are outside of the controlled environment of a clinical trial, their experiences may be considered to be more "real-world." A multi-national chart review has shown that the success of treatments given through expanded access was mirrored in clinical trials, then after approval and mass [...]

2017-11-07T12:22:07+00:00November 17, 2017|General|

How could research of stem cells improve the delivery of cancer drugs to metastatic tumors?

Recent research of stem cells in mice has produced a more precise way to deliver chemotherapy to the tumor microenvironment of metastatic cancer. As opposed to targeting cancer cells directly, as other stem cell research has aimed to achieve, this delivery method targets the cells in their home, which could have a greater effect on [...]

2017-11-07T12:22:13+00:00November 14, 2017|General|

Could wider inclusion of minority patients in clinical trials actually lower the cost of healthcare overall?

Lack of accurate data regarding potential side effects or differences in effectiveness in treatments between white Americans and patients of different ethnic backgrounds often leads to less affordable options of care. When drugs have been studied, and minorities left out, treatments that are less effective could lead to greater numbers of hospitalizations, driving up the [...]

2017-11-07T12:22:35+00:00November 10, 2017|General|

New Waiver in IRB Process Speeds FDA Single Patient Expanded Access Approval; Updated Information available on WCGF website.

On October 3, 2017, Dr. Scott Gottlieb, FDA Commissioner, testified before the US House of Representatives Subcommittee on Health, Committee on Energy and Commerce. He announced a significant change to the way that IRB may review single patient expanded access request involving investigational drugs or biologics. This change, which permits an IRB chair or designee [...]

2018-05-25T16:30:55+00:00November 8, 2017|General|

What can a new atlas of DNA tell us about genetic probabilities?

Researchers funded by the National Institutes of Health (NIH) have completed an atlas of human DNA that influence gene expression. Gene expression is shown through observable traits like eye color or disease risk; this research has shown how some genes are turned off and on. Previously, such information was not available at this scale. However, [...]

2017-11-07T12:22:28+00:00November 3, 2017|General|

Expanded access allows patients to receive innovative new drugs. How often does the FDA approve patients’ requests?

The FDA's expanded access program has allowed many desperately ill patients to receive experimental treatments in an effort to save lives. Just last fiscal year, over 1,700 requests were made by patients to access experimental treatments. The Food and Drug Administration's Center for Drug Evaluation and Research and their Center for Biologics Evaluation and Research combined [...]

2017-09-27T06:08:43+00:00October 31, 2017|General|

What is a .@US_FDA priority review voucher and how does it expand opportunity for #medicalresearch of #rarediseases?

The priority review voucher program incentivizes pharmaceutical companies to research drugs for very rare diseases. When a drug developer researches a rare disease, a voucher is received by that organization from the FDA to move another treatment, often for a more common disease, through the regulatory process more quickly. How does this program work? http://bit.ly/2f5RXjm

2017-09-27T06:08:35+00:00October 27, 2017|General|
Load More Posts